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Articles
Restenosis and risk of stroke after stenting or 
endarterectomy for symptomatic carotid stenosis in the 
International Carotid Stenting Study (ICSS): 
secondary analysis of a randomised trial
Leo H Bonati, John Gregson, Joanna Dobson, Dominick J H McCabe, Paul J Nederkoorn, H Bart van der Worp, Gert J de Borst, Toby Richards, 
Trevor Cleveland, Mandy D Müller, Thomas Wolff, Stefan T Engelter, Philippe A Lyrer, Martin M Brown, for the International Carotid Stenting 
Study investigators*
Summary
Background The risk of stroke associated with carotid artery restenosis after stenting or endarterectomy is unclear. 
We aimed to compare the long-term risk of restenosis after these treatments and to investigate if restenosis causes 
stroke in a secondary analysis of the International Carotid Stenting Study (ICSS).
Methods ICSS is a parallel-group randomised trial at 50 tertiary care centres in Europe, Australia, New Zealand, and 
Canada. Patients aged 40 years or older with symptomatic carotid stenosis measuring 50% or more were randomly 
assigned either stenting or endarterectomy in a 1:1 ratio. Randomisation was computer-generated and done centrally, 
with allocation by telephone or fax, stratified by centre, and with minimisation for sex, age, side of stenosis, and 
occlusion of the contralateral carotid artery. Patients were followed up both clinically and with carotid duplex 
ultrasound at baseline, 30 days after treatment, 6 months after randomisation, then annually for up to 10 years. 
We included patients whose assigned treatment was completed and who had at least one ultrasound examination 
after treatment. Restenosis was defined as any narrowing of the treated artery measuring 50% or more (at least 
moderate) or 70% or more (severe), or occlusion of the artery. The degree of restenosis based on ultrasound velocities 
and clinical outcome events were adjudicated centrally; assessors were masked to treatment assignment. Restenosis 
was analysed using interval-censored models and its association with later ipsilateral stroke using Cox regression. 
This trial is registered with the ISRCTN registry, number ISRCTN25337470. This report presents a secondary 
analysis, and follow-up is complete. 
Findings Between May, 2001, and October, 2008, 1713 patients were enrolled and randomly allocated treatment 
(855 were assigned stenting and 858 endarterectomy), of whom 1530 individuals were followed up with ultrasound 
(737 assigned stenting and 793 endarterectomy) for a median of 4·0 years (IQR 2·3–5·0). At least moderate 
restenosis (≥50%) occurred in 274 patients after stenting (cumulative 5-year risk 40·7%) and in 217 after 
endarterectomy (29·6%; unadjusted hazard ratio [HR] 1·43, 95% CI 1·21–1·72; p<0·0001). Patients with at least 
moderate restenosis (≥50%) had a higher risk of ipsilateral stroke than did individuals without restenosis in the 
overall patient population (HR 3·18, 95% CI 1·52–6·67; p=0·002) and in the endarterectomy group alone (5·75, 
1·80–18·33; p=0·003), but no significant increase in stroke risk after restenosis was recorded in the stenting group 
(2·03, 0·77–5·37; p=0·154; p=0·10 for interaction with treatment). No difference was noted in the risk of severe 
restenosis (≥70%) or subsequent stroke between the two treatment groups.
Interpretation At least moderate (≥50%) restenosis occurred more frequently after stenting than after endarterectomy 
and increased the risk for ipsilateral stroke in the overall population. Whether the restenosis-mediated risk of stroke 
differs between stenting and endarterectomy requires further research.
Funding Medical Research Council, the Stroke Association, Sanofi-Synthélabo, and the European Union.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access Article under the CC BY license.
Introduction
Endarterectomy and stenting aim to lower the long-term 
risk of stroke in patients with atherosclerotic disease of 
the carotid artery. Findings of randomised trials of 
these procedures for treatment of symptomatic carotid 
stenosis show that, by comparison with endarterectomy, 
stenting has a higher risk of stroke, particularly in older 
patients, but has lower risks of myocardial infarction, 
cranial nerve palsy, and access-site haematoma.1–4 
Beyond the initial periprocedural period, stenting and 
endarterectomy were equally effective at preventing 
recurrent stroke, but findings on long-term patency of 
the treated carotid artery after each procedure have 
been conflicting.5–10 Importantly, the question of 
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whether residual or recurrent stenosis after treatment 
increases the risk of recurrent stroke has not been 
answered definitively.
The International Carotid Stenting Study (ICSS) is the 
largest randomised trial to date comparing stenting 
with endarterectomy for symptomatic carotid stenosis. 
We previously reported results up to 10 years after 
randomisation, which showed that each procedure was 
equally effective at preventing fatal or disabling stroke—
the primary outcome measure of the trial.9 Moreover, we 
reported no difference in the long-term risk of 
severe (≥70%) restenosis after either procedure.
The aims of this prespecified secondary analysis of ICSS 
were to quantify the long-term risk of at least moderate 
(≥50%) restenosis up to 10 years after randomisation, 
to ascertain whether restenosis pre disposed to a higher 
risk of subsequent stroke after either procedure, and to 
investigate the risk factors predisposing to restenosis. 
We postulated that moderate or higher (≥50%) restenosis 
would be more frequent after stenting than endarterectomy 
and might predispose to a higher risk of recurrent stroke 
during long-term follow-up.
Methods
Participants
ICSS included patients with carotid stenosis associated 
with ipsilateral transient ischaemic attack or stroke 
symptoms within the 12 months before inclusion. 
We recruited patients from 50 tertiary care centres in 
Europe, Australia, New Zealand, and Canada (appendix). 
The trial was approved by the Northwest Multicentre 
Research Ethics Committee in the UK. Individual 
participating centres also obtained site-specific approval 
from their local research ethics committees. All patients 
provided written informed consent to participate in the 
trial before randomisation. Details on centre require-
ments, patients’ eligibility criteria, randomisation, and 
treatment have been published previously.3,9,11 The trial 
protocol is available on the trial website.
Randomisation and masking
In brief, patients aged 40 years or older with symptom-
atic atherosclerotic carotid stenosis (≥50% diameter 
reduc tion), who were judged by local investigators 
equally suited for both treatments, were randomly 
assigned to treatment by stenting or endarterectomy in a 
1:1 ratio. Randomisation was done by telephone or fax 
using a computerised service provided by the Oxford 
Clinical Trials Service Unit, which was not involved in 
other aspects of the trial. Randomisation was stratified by 
centre and was minimised for sex, age, side of stenosis, 
and occlusion of the contralateral carotid artery. Patients 
and investigators were aware of the treatment 
assignment.
Research in context
Evidence before this study
We searched the Cochrane Stroke Group Trials Register, the 
Cochrane Central Register of Controlled Trials, MEDLINE, Embase, 
and Science Citation Index up to April, 2016, for randomised 
controlled trials published in the English language comparing 
carotid artery stenting versus carotid endarterectomy in patients 
with symptomatic or asymptomatic carotid stenosis. Only trials 
using primary carotid stenting in their endovascular treatment 
group—ie, with routine placement of a stent—were included. 
We compared the odds of at least moderate (≥50% narrowing of 
the lumen) carotid restenosis or occlusion, and of severe (≥70%) 
restenosis or occlusion. The trials used different ultrasound criteria 
to measure stenosis severity. Eight trials have reported 
severe (≥70%) restenosis, three of which additionally reported at 
least moderate (≥50%) restenosis. Only one trial showed a 
significantly increased incidence of severe (≥70%) restenosis after 
stenting than after endarterectomy, whereas in the other 
seven trials no difference was noted. At least moderate (≥50%) 
restenosis occurred significantly more often after stenting than 
after endarterectomy in two trials (one of which was very small), 
whereas in another very small trial no difference was noted. 
In a systematic review, the presence of severe (≥70%) carotid 
restenosis or occlusion increased the risk of stroke after 
endarterectomy but not after stenting. However, whether stroke 
risk is already increased at lower degrees of restenosis (ie, ≥50%) 
remained unclear.
Added value of this study
The International Carotid Stenting Study (ICSS) is the largest 
randomised trial reporting long-term restenosis of various 
severity and subsequent risks of stroke after stenting versus 
endarterectomy for treatment of symptomatic carotid 
stenosis. The results of the current analysis show that 
moderate or higher (≥50%) restenosis is significantly more 
frequent after stenting compared with endarterectomy, but 
severe (≥70%) restenosis rates did not differ. These findings 
accord with previous data. ICSS is the first trial to show that the 
presence of at least moderate (≥50%) restenosis increases the 
risk for subsequent ipsilateral stroke and for stroke in any 
territory. This increased stroke risk was only significant in the 
endarterectomy group.
Implications of all the available evidence
Carotid artery stenting is associated with a higher long-term 
risk for moderate or higher restenosis (leading to 50% or more 
luminal narrowing) than is endarterectomy. Carotid restenosis 
increases the risk for stroke, but this risk gain might be more 
pronounced after endarterectomy than after stenting. 
Further evidence is needed to assess the usefulness of regular 
follow-up of patients after carotid revascularisation with duplex 
ultrasound and to ascertain whether repeat revascularisation is 
beneficial in those with restenosis.
For the protocol see 
http://www.cavatas.com
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Procedures
Carotid imaging was done before randomisation to 
confirm the diagnosis of stenosis measuring 50% or 
more. The diagnosis was made by either selective digital 
subtraction angiography or concordant findings on 
extracranial carotid duplex ultrasound and non-invasive 
angiography (magnetic resonance angiography [MRA] 
or computed tomography angiography [CTA]). The inter-
ven tionist used their discretion to choose stents and 
cerebral protection devices, but they had to be CE-marked 
and approved by the Trial Steering Committee. Surgeons 
could do either standard or eversion endarterectomy, 
under local or general anaesthesia, with or without the 
use of shunts or patches. We judged stenting complete 
when a stent was placed across the stenosis, and 
we deemed endarterectomy complete when the plaque 
was removed and the arteriotomy wound closed. 
All patients received medical care including antiplatelet 
therapy or anticoagulation, if indicated, and control of 
vascular risk factors.
We followed up patients at 30 days after treatment then 
at 6 months after randomisation and annually thereafter. 
The duration of follow-up was initially planned for 
5 years but was extended to 10 years after randomisation 
in patients able and willing to continue.
The protocol specified that carotid duplex ultrasound 
was to be done at every follow-up visit. Peak systolic 
velocities in the common carotid artery and internal 
carotid artery, and end diastolic velocity in the internal 
carotid artery were recorded on duplex ultrasound and 
reported to the central trial office. One investigator 
(LHB)—who was masked to treatment allocation and 
date of follow-up—graded stenosis according to pre-
defined criteria that equate well with stenosis severity 
measured on catheter angiography, using the North 
American Symptomatic Carotid Endarterectomy Trial 
(NASCET) method of estimating stenosis.12 To quantify 
the severity of stenosis, we used a cutoff for peak systolic 
velocity in the internal carotid artery greater than 
1·3 m/s for at least moderate (≥50%) stenosis and 
greater than 2·1 m/s for severe (≥70%) stenosis. We also 
considered the end diastolic velocity in the internal 
carotid artery and the ratio of peak systolic velocities in 
the internal carotid artery to the common carotid artery 
(appendix).13 No correction was made for the presence of 
a stent when measuring stenosis, based on the results 
of a study of a subset of patients treated with stents in 
ICSS, which showed similar estimates of stenosis 
severity from simultaneous CTA and duplex ultrasound 
exam inations.14 Ultrasound velocity measurements were 
not available from a few study centres; in these cases, 
we used the percentage stenosis reported by the local 
ultrasonographer and investigator. Additional carotid 
ultrasound and other imaging studies (eg, MRA or CTA) 
could be done if needed outside the regular follow-up 
intervals—eg, if patients had recurrent cerebrovascular 
events. In these cases, the same investigator (LHB) 
quantified the degree of stenosis by the NASCET 
method and these results were also included in the 
present analysis.
Outcomes
The primary outcome of ICSS was fatal or disabling 
stroke, and this outcome has been reported previously.9 
The protocol of ICSS specified stenosis greater than 
70% or occlusion during follow-up as a secondary 
outcome measure. For this study, we defined moderate 
or higher (≥50%) restenosis as stenosis of the treated 
carotid artery measuring 50% or greater, including 
occlusion, seen at any time during follow-up after 
completion of treatment. We defined severe (≥70%) 
restenosis as any stenosis of 70% or greater, or 
occlusion. The definition of restenosis did not 
distinguish between recurrent stenosis and residual 
stenosis present immediately after treatment.
An independent endpoint committee masked to 
treatment allocation adjudicated major clinical outcome 
events. In the present analysis, we investigated whether 
restenosis caused ipsilateral stroke of any severity—
ie, occurring in the territory supplied by the treated 
carotid artery—and stroke in any vascular territory. 
We defined stroke clinically as a rapidly developing 
clinical syndrome of focal retinal or cerebral dysfunction 
lasting more than 24 h or leading to early death, with no 
other apparent non-vascular cause.
Statistical analysis
We did the present analysis per protocol. We only 
included patients in whom the randomly allocated 
treatment was initiated and completed and in whom 
at least one post-procedural ultrasound follow-up 
examin ation was done and available for analysis. 
We excluded patients who did not have revascularisation, 
those who underwent aborted procedures, and those 
who crossed over to receive the alternative procedure. 
We censored patients at the time of any further ipsilateral 
revascularisation procedure during follow-up, at their 
last ultrasound examination, or death. We assumed 
non-informative censoring. We compared time to 
censoring at the last ultrasound examination between 
treatment groups using the log-rank test to check 
whether the duration of ultrasound follow-up was 
similar in both groups. Because the restenosis outcome 
was interval-censored (ie, restenosis was only known to 
have occurred at some point between the previous 
ultrasound scan and the one showing restenosis), 
we analysed time to restenosis using a generalised 
non-linear model, which assumes proportional hazards, 
and the treatment effect parameter estimate can be 
interpreted as a log hazard ratio (HR).13,15 We tested 
proportionality of hazards via interactions with follow-up 
periods.
We used a likelihood ratio test to calculate the treatment 
effect p value. We calculated HRs for restenosis, with 
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endarterectomy as the reference group, both without 
adjustment and after adjustment for patients’ baseline 
characteristics associated independently with restenosis. 
We identified such baseline characteristics using forward 
stepwise selection in a generalised non-linear model that 
included treatment as a covariate. In a post-hoc analysis, 
we additionally checked the association between statin 
use at 30 days after treatment and restenosis during 
follow-up (data for statin use at baseline were not gathered 
in ICSS). We calculated the cumulative incidence of 
restenosis at 1 year and 5 years after treatment using the 
Kaplan-Meier method, with time to restenosis set to the 
midpoint between the previous normal scan and the one 
showing restenosis. We truncated Kaplan-Meier plots 
of time to restenosis at 7 years, because the number of 
patients in whom ultrasound follow-up was continued 
beyond this timepoint was relatively small.
To investigate the association between occurrence of 
restenosis and subsequent stroke during follow-up, 
we compared event hazards between patients without 
restenosis (starting from 30 days after the initial 
revascularisation procedure) and those with restenosis 
(beginning at the first scan showing restenosis), using 
Cox proportional hazards models. We used a time-updated 
covariate,16 whereby a patient with restenosis was included 
in the no restenosis group up until the scan showing 
restenosis, thereafter they were in the restenosis group. 
We counted strokes occurring before the scan showing 
restenosis in the no restenosis group (appendix). 
We censored patients at the time of their stroke and 
disregarded further ultrasound scans. We calculated HRs 
of outcome events, with no restenosis as the reference 
group, without adjustment and again with adjustment for 
baseline characteristics associated independently with 
restenosis. We did this analysis for both moderate or 
higher (≥50%) restenosis and severe (≥70%) restenosis.
We did all statistical analyses in Stata 14.1 and used the 
intcens command for models for interval-censored data. 
All reported p values are two-sided, with a value less than 
0∙05 judged significant. We made no adjustment for 
multiple comparisons.
This study is registered with the ISRCTN registry, 
number ISRCTN25337470.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
report. LHB, JG, JD, and MMB had full access to all data 
in the study. The corresponding author had final 
responsibility for the decision to submit for publication.
Results
Between May, 2001, and October, 2008, 1713 patients 
were recruited to ICSS, of whom 855 were randomly 
assigned to stenting and 858 to endarterectomy (figure 1). 
Ultrasound follow-up was done in 1530 (97%) of 
1583 patients who completed treatment, 737 in the 
stenting and 793 in the endarterectomy groups, with a 
median duration of follow-up of 4·0 years (IQR 2·3–5·0) 
and a maximum follow-up of 10 years. No difference was 
noted in the duration of ultrasound follow-up between 
the two treatment groups. Baseline characteristics of 
patients included in the restenosis analysis were similar 
in the two treatment groups and to the full ICSS trial 
population (table 1).
At least moderate (≥50%) restenosis occurred more 
frequently in the stenting group (n=274 patients) than 
in the endarterectomy group (n=217), with resulting 
cumulative 5-year risks of 40·7% versus 29·6% 
(unadjusted HR 1·43, 95% CI 1·21–1·72; p<0·0001; 
table 2, figure 2A). No difference was noted between the 
two treatment groups in long-term risk of severe (≥70%) 
carotid restenosis or occlusion, which occurred in 
10·6% of patients in the stenting group and 8·5% of 
patients in the endarterectomy group in the first 5 years 
(unadjusted HR 1·20, 95% CI 0·86–1·69; p=0·27; table 2, 
figure 2B). 29 patients had an occlusion of the treated 
carotid artery during follow-up, 16 in the stenting group 
and 13 in the endarterectomy group.
In the forward stepwise selection analysis of variables 
associated independently with restenosis, associations 
Figure 1: Trial profile
858 assigned to endarterectomy
1713 patients randomised
821 endarterectomy initiated
793 analysed by ultrasound
2 endarterectomy aborted
26 no ultrasound post procedure
1 withdrew all consent immediately
after randomisation
15 crossed over to stenting
1 anatomy unsuitable
6 medical contraindications
4 refused treatment
4 other reasons
21 underwent no procedure
2 died before intended procedure
3 disabling stroke before intended
procedure
9 artery occluded
1 artery less than 50% stenosed
3 medical contraindications
1 refused treatment
2 other reasons
855 assigned to stenting
828 stenting initiated
737 analysed by ultrasound
64 stenting aborted
27 no ultrasound post procedure
2 withdrew all consent immediately
after randomisation
9 crossed over to endarterectomy
2 anatomy unsuitable
3 medical contraindications
1 refused treatment
3 other reasons
16 underwent no procedure
1 disabling stroke before intended
procedure
5 artery occluded
3 artery less than 50% stenosed
1 anatomy unsuitable
3 other medical contraindications
3 other reasons
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were very similar in both stenting and endarterectomy 
groups. Therefore, any association between baseline 
characteristics and risk of restenosis was analysed 
in both treatment groups combined. Older age, 
female sex, current or past smoking, non-insulin 
dependent diabetes, a history of angina, a greater extent 
of stenosis in the contralateral carotid artery at 
randomisation, raised systolic and diastolic blood 
pressures at randomisation, and higher total serum 
cholesterol at randomisation increased the risk of 
restenosis independently of each other and of treatment 
assignment (appendix). Statin use at 30 days after 
treatment was not associated with any change in the risk 
of restenosis. Greater contralateral carotid stenosis and 
non-insulin dependent diabetes also predicted severe 
restenosis. HRs for restenosis between stenting and 
endarterectomy were very similar after adjustment for 
these independent predictors (table 2).
Stenting group Endarterectomy group
Included in analyses All patients Included in analyses All patients
Demographics
Age (years) 70·0 (63·6–76·5) 70·8 (64·4–76·9) 70·6 (64·1–76·9) 70·8 (64·1–76·9)
Men 513/737 (70%) 601/853 (70%) 561/793 (71%) 606/857 (71%)
Women 224/737 (30%) 252/853 (30%) 232/793 (29%) 251/857 (29%)
Vascular risk factors and history
Treated hypertension 503/730 (69%) 587/843 (70%) 552/787 (70%) 596/851 (70%)
Systolic blood pressure (mm Hg) 147·4 (24·1) 147·0 (24·0) 146·0 (23·7) 146·0 (23·6)
Diastolic blood pressure (mm Hg) 79·3 (11·8) 79·2 (11·7) 78·2 (12·6) 78·3 (12·7)
Diabetes 162/737 (22%) 184/853 (22%) 165/793 (21%) 188/857 (22%)
Non-insulin dependent 116/730 (16%) 134/843 (16%) 128/787 (16%) 147/851 (17%)
Insulin dependent 46/730 (6%) 50/843 (6%) 37/787 (5%) 41/851 (5%)
Treated hyperlipidaemia 459/730 (63%) 522/843 (62%) 523/787 (66·5) 563/851 (66%)
Total cholesterol (mmol/L) 4·9 (1·3) 4·8 (1·3) 4·9 (1·3) 4·9 (1·3)
Current smoker 182/730 (25%) 205/843 (24%) 183/787 (23%) 198/851 (23%)
Ex-smoker 352/730 (48%) 408/843 (48%) 392/787 (50%) 424/851 (50%)
Angina in past 6 months 70/730 (10%) 83/843 (10%) 69/787 (9%) 77/851 (9%)
Previous myocardial infarction 126/730 (17%) 151/843 (18%) 145/787 (18%) 156/851 (18%)
Previous coronary-artery bypass graft 95/730 (13%) 109/843 (13%) 106/787 (13%) 116/851 (14%)
Atrial fibrillation 44/730 (6%) 57/843 (7%) 52/787 (7%) 59/851 (7%)
Other cardioembolic source 15/730 (2%) 19/843 (2%) 16/787 (2%) 16/851 (2%)
Cardiac failure 21/730 (3%) 23/843 (3%) 40/787 (5%) 47/851 (6%)
Peripheral artery disease 123/730 (17%) 139/843 (16%) 122/787 (16%) 136/851 (16%)
Degree of symptomatic carotid stenosis*
50–69% 75/737 (10%) 92/853 (11%) 71/793 (9%) 76/857 (9%)
70–99% 662/737 (90%) 761/853 (89%) 722/793 (91%) 781/857 (91%)
Degree of contralateral carotid stenosis*
<50% 495/737 (67%) 565/853 (66%) 522/793 (66%) 561/857 (65%)
50–69% 104/737 (14%) 128/853 (15%) 131/793 (17%) 142/857 (17%)
70–79% 93/737 (13%) 105/853 (12%) 99/793 (12%) 110/857 (13%)
Occluded 43/737 (6%) 49/853 (6%) 35/793 (4%) 37/857 (4%)
Unknown 2/737 (<1%) 6/853 (1%) 6/793 (1%) 7/857 (1%)
Most recent ipsilateral event before randomisation†
Retinal ischaemia (amaurosis fugax or retinal infarct) 157/728 (22%) 174/840 (21%) 153/781 (20%) 165/844 (20%)
Transient ischaemic attack 239/737 (32%) 273/853 (32%) 280/793 (35%) 303/857 (35%)
Ischaemic hemispheric stroke 332/737 (45%) 393/853 (46%) 348/793 (44%) 376/857 (44%)
Unknown 9/737 (1%) 13/853 (2%) 12/793 (2%) 13/857 (2%)
Time from event to procedure (days) 35 (15–82) 35 (15–82) 40 (18–87) 40 (18–87)
Treatment within 14 days of event 181/737 (25%) 206/837 (25%) 144/791 (18%) 151/834 (18%)
Data are either median (IQR), number of patients/total number (%), or mean (SD). Some totals do not add up to 100% because of rounding. *Degree of stenosis reported by 
randomising centre according to the measure used in the North American Symptomatic Carotid Endarterectomy Trial or a non-invasive equivalent. †If two events were 
reported on the same day, the more severe event was counted. 
Table 1: Baseline characteristics
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In both treatment groups combined, patients with at 
least moderate (≥50%) restenosis were at increased risk of 
subsequent ipsilateral stroke, with a cumulative risk at 
6 years of 6·9% versus 2·5% for patients without 
restenosis (unadjusted HR 3·18, 1·52–6·67; p=0·002; 
figure 3A, table 3). 6-year cumulative risk of stroke in any 
territory was also increased to 9·6% in patients with 
moderate or higher (≥50%) restenosis versus 5·6% in 
those without restenosis (1·96, 1·12–3·45; p=0·019; 
figure 3D, table 3). Analysis by treatment group showed 
that the restenosis-mediated increase in risk for these 
events was significant in the endarterectomy group, with a 
6-year cumulative risk of ipsilateral stroke of 5·8% in 
patients with moderate or higher (≥50%) restenosis versus 
1·3% in those without restenosis (unadjusted HR 5·75, 
1·80–18·33; p=0·003; figure 3C, table 3) and a 6-year risk 
of any stroke of 6·5% in patients with at least moderate 
(≥50%) restenosis and 3·4% in those without restenosis 
(3·12, 1·22–7·99; p=0·018; figure 3F, table 3). No 
significant increase in risk was noted in the stenting 
group, with 6-year cumulative risk of ipsilateral stroke of 
7·8% in patients with at least moderate (≥50%) restenosis 
versus 3·8% in those without restenosis (unadjusted 
HR 2·03, 0·77–5·37; p=0·154; figure 3B, table 3) and risk 
of any stroke of 12·0% in patients with moderate or higher 
(≥50%) restenosis versus 8·1% in those without restenosis 
(1·53, 0·75–3·10, p=0·24; figure 3E, table 3). The formal 
test of a statistical interaction between type of treatment 
(stenting or endarterectomy) and the increase in ipsilateral 
stroke risk caused by restenosis resulted in p=0·10. 
Associations remained significant after adjust ment for 
patients’ baseline characteristics predicting restenosis. 
The presence of severe (≥70%) restenosis or occlusion was 
not associated with an increase in subsequent stroke, but 
the power of this analysis was limited by the few patients 
with severe (≥70%) stenosis (table 4).
Discussion
In this secondary analysis of ICSS, the long-term risk of 
moderate or higher (≥50%) restenosis, or occlusion of 
the carotid artery, was significantly higher after stenting 
than after endarterectomy. As previously reported,9 the 
risk of severe (≥70%) carotid restenosis, or occlusion, did 
not differ between treatment groups. Among patients 
in both groups combined, those with at least 
Stenting (n=737) Endarterectomy (n=793) Stenting vs endarterectomy
Unadjusted HR (95% CI) p value Adjusted HR (95%CI)* p value
At least moderate (≥50%) restenosis or occlusion
Total number of patients with outcome 274 217 1·43 (1·21–1·72) <0·0001 1·39 (1·14–1·69) 0·001
Cumulative 1-year incidence (95% CI) 27·8% (24·7–31·3) 21·0% (18·3–24·1) ·· ·· ·· ··
Cumulative 5-year incidence (95% CI) 40·7% (36·9–44·8) 29·6% (26·3–33·2) ·· ·· ·· ··
Severe (≥70%) restenosis or occlusion
Total number of patients with outcome 72 62 1·20 (0·86–1·69) 0·27 1·17 (0·83–1·67) 0·36
Cumulative 1-year incidence (95% CI) 6·9% (5·2–9·0) 5·2% (3·8–7·0) ·· ·· ·· ··
Cumulative 5-year incidence (95% CI) 10·6% (8·4–13·3) 8·5% (6·7–10·9) ·· ·· ·· ··
HR=hazard ratio. *Adjusted for baseline characteristics predictive of restenosis (appendix). 
Table 2: Carotid artery restenosis or occlusion after stenting compared with endarterectomy
Figure 2: Cumulative incidence of (A) at least moderate (≥50%) carotid artery 
restenosis or occlusion and (B) severe (≥70%) carotid artery restenosis or 
occlusion after completed treatment
Cumulative incidence was estimated by life-table analysis. Plots stop at 7 years’ 
follow-up because the number of patients at risk beyond that time was fewer 
than 100, but analyses were based on all follow-up data (maximum 10 years). 
HR=unadjusted hazard ratio.
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moderate (≥50%) restenosis had a significantly increased 
risk of subsequent ipsilateral stroke compared with those 
without restenosis. Analysed separately, the increase in 
stroke risk in patients with restenosis compared with 
those without restenosis was significantly higher after 
initial treatment with endarterectomy, but not after initial 
treatment with stenting.
Findings of randomised trials have shown that among 
patients with symptomatic carotid stenosis, stenting is 
associated with a greater risk of non-disabling procedural 
stroke than is endarterectomy, but the long-term efficacy at 
preventing recurrent stroke after the procedural period is 
equivalent for each procedure.5,8–10 Despite these reassuring 
data for stroke prevention, concerns have remained about 
the risk of restenosis after treatment and whether 
restenosis increases the long-term risk of recurrent stroke. 
In the Carotid and Vertebral Artery Transluminal 
Angioplasty Study (CAVATAS),13 endovascular treatment 
Figure 3: Kaplan-Meier curves of time to (A–C) ipsilateral stroke and (D–F) stroke in any territory with and without at least moderate (≥50%) carotid artery 
restenosis or occlusion
HR=unadjusted hazard ratio.
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HR (95% CI) p value Events with 
restenosis 
(n/N)
Events without 
restenosis 
(n/N)
HR (95% CI) p value Events with 
restenosis 
(n/N)
Events without 
restenosis 
(n/N)
HR (95% CI) p value
Ipsilateral stroke
Unadjusted 3·18 (1·52–6·67) 0·002 7/185 12/550 2·03 (0·77–5·37) 0·154 6/137 6/586 5·75 (1·80–18·33) 0·003
Adjusted* 2·98 (1·39–6·40) 0·005 7/185 12/550 2·06 (0·75–5·63) 0·161 6/137 6/586 5·83 (1·76–19·33) 0·004
Any stroke
Unadjusted 1·96 (1·12–3·45) 0·019 12/185 27/550 1·53 (0·75–3·10) 0·24 7/137 15/586 3·12 (1·22–7·99) 0·018
Adjusted* 1·81 (1·00–3·26) 0·048 12/185 27/550 1·46 (0·70–3·04) 0·312 7/137 15/586 3·48 (1·32–9·15) 0·012
The first 30 days after a procedure, and patients with restenosis in the first 30 days, are excluded from this analysis. Patients were censored at the time of stroke or at any ipsilateral procedure during follow-up. 
HR=hazard ratio. *Adjusted for predictors of restenosis (appendix). Only participants with complete information on these baseline risk factors were included in the adjusted comparisons.
Table 3: Association of at least moderate (≥50%) carotid artery restenosis with subsequent outcome events
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was compared with endarterectomy in patients with 
predominantly symptomatic carotid stenosis, using the 
same criteria for grading restenosis as in ICSS. The 
cumulative 5-year risk of moderate or higher resten-
osis (≥50%) was 59% after endovascular treatment and 
32% after endarterectomy, and risks of severe restenosis 
(≥70%) or occlusion were 31% and 11%, respectively 
(p<0·0001). However, most patients in the endovascular 
arm of this early trial were treated by balloon angioplasty 
alone, without insertion of stents. Since then, several trials 
comparing primary stenting versus endarterectomy for 
symptomatic carotid stenosis with ultrasound follow-up 
have published mid-term and long-term outcomes. In the 
Stent-Supported Percutaneous Angioplasty of the Carotid 
Artery versus Endarterectomy (SPACE) trial,5 rates of 
severe restenosis (≥70%) 2 years after stenting were 
significantly higher than after endarterectomy (10∙7% vs 
4∙6%; p=0·0009), using ultrasound velocity criteria 
established at the individual local centres. In the 
Endarterectomy Versus Angioplasty in Patients With 
Symptomatic Severe Carotid Stenosis (EVA-3S) trial,6 the 
proportion of patients with moderate or higher 
(≥50%) restenosis at 3 years—defined by planimetric 
measurements on ultrasound—was higher after stenting 
than after endarterectomy (13% vs 5%; p=0·02). However, 
the incidence of velocity-defined severe restenosis (≥70%), 
using the same cutoff for peak systolic velocity in the 
internal carotid artery as in our study (≥2·1 m/s), did not 
differ at either 5 years (stenting 2∙3% vs endarterectomy 
4∙2%) or 10 years (5·0% vs 8·3%) after treatment.8 
Likewise, in the Carotid Revascularization Endarterectomy 
versus Stenting Trial (CREST),10 in which 1159 patients 
with symptomatic and 1032 patients with asymptomatic 
carotid stenosis were followed up by ultrasound, the 
combined 10-year incidence of severe carotid restenosis 
(≥70%, using a cutoff for peak systolic velocity in 
the internal carotid artery of ≥3·0 m/s) or repeat 
revascularisation did not differ between the stenting 
(12·2%) and endarterectomy (9·7%) groups (HR 1·24, 
95% CI 0·91–1·70). In a previous analysis by the CREST 
investigators,7 restenosis 3 years after treatment was 
compared using several cutoffs for peak systolic velocity. 
Severe restenosis—defined by a peak systolic velocity in 
the internal carotid artery of 2·1 m/s or higher—was 
significantly more frequent after stenting than after 
endarterectomy (14·8% vs 10·5%; p=0·02), whereas when 
a cutoff for peak systolic velocity in the internal carotid 
artery of 3·0 m/s or greater was used, no difference was 
noted (6·0% vs 6·3%; p=0·58). The frequency of 
restenosis equivalent to our measure of 50% or greater—
ie, a cutoff for peak systolic velocity in the internal carotid 
artery of greater than 1·3 m/s—was not reported.
Some investigators have recommended using higher 
cutoffs for peak systolic velocity on duplex ultrasound for 
a given degree of stenosis in stented carotid arteries 
compared with native arteries because of possible 
alterations in arterial wall elasticity after stenting.17,18 
However, in ICSS, a comparison was done of duplex 
ultrasound velocities and degree of restenosis determined 
by CTA in a subset of 103 patients treated with stents.14 
The optimum cutoff for peak systolic velocity in the 
internal carotid artery was greater than 1·25 m/s, which 
is similar to that used in our study for identifying 
moderate or higher (≥50%) restenosis. Hence, we used 
the same standardised velocity criteria in both treatment 
groups in this current analysis. The threshold for peak 
systolic velocity in the internal carotid artery we used was 
also similar to one recommended in a consensus paper 
(>1·25 m/s).19
We identified older age, female sex, current or past 
smoking, non-insulin dependent diabetes, history of 
angina, greater degree of stenosis in the contralateral 
carotid artery at randomisation, higher systolic or 
diastolic blood pressure at randomisation, and higher 
total serum cholesterol at randomisation as independent 
predictors of restenosis. In CREST, women, patients 
with diabetes, and those with dyslipidaemia were also at 
greater risk of restenosis after either treatment, as were 
smokers after endarterectomy.7 Researchers on the 
CAVATAS trial also identified smoking as an independent 
risk factor for restenosis.13 Although it is intuitive that 
vascular risk factors increase the risk for restenosis, the 
Both groups Stenting Endarterectomy
HR (95% CI) p value Events with 
restenosis 
(n/N)
Events without 
restenosis 
(n/N)
HR (95% CI) p value Events with 
restenosis 
(n/N)
Events without 
restenosis 
(n/N)
HR (95% CI) p value
Any stroke
Unadjusted 1·79 (0·64–4·99) 0·263 3/38 37/569 2·06 (0·63–6·82) 0·234 1/34 23/611 1·34 (0·18–10·10) 0·774
Adjusted* 1·64 (0·58–4·62) 0·346 3/38 37/569 1·96 (0·58–6·59) 0·278 1/34 23/611 1·35 (0·18–10·31) 0·772
Ipsilateral stroke
Unadjusted 1·66 (0·39–7·03) 0·489 1/38 18/569 1·37 (0·18–10·49) 0·761 1/34 13/611 2·20 (0·28–16·99) 0·450
Adjusted* 1·46 (0·34–6·22) 0·613 1/38 18/569 1·25 (0·16–9·80) 0·830 1/34 13/611 1·83 (0·23–14·56) 0·568
The first 30 days after a procedure, and patients with restenosis in the first 30 days, are excluded from this analysis. Patients were censored at the time of stroke or at any ipsilateral procedure during follow-up. 
HR=hazard ratio. *Adjusted for predictors of restenosis (appendix). Only participants with complete information on these baseline risk factors were included in the adjusted comparisons.
Table 4: Association of severe (≥70%) carotid artery restenosis with subsequent outcome events
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reason why female sex was associated with increased 
risk of restenosis is uncertain. However, this association 
might relate to the fact that the diameter of carotid 
arteries is smaller in women compared with men; thus, 
a given width of intimal hyperplasia might lead to a 
greater degree of stenosis in women than in men.20
Our finding that at least moderate (≥50%) restenosis 
on routine ultrasound follow-up conferred an increased 
risk of stroke over time has important implications. 
In the CAVATAS trial,13 patients who developed severe 
restenosis (≥70%) within the first year after treatment 
had a higher risk of subsequent ipsilateral transient 
ischaemic attack or stroke combined, but no increase in 
risk for ipsilateral stroke alone. However, the trial had a 
third fewer patients than in ICSS. CREST also reported a 
higher risk of ipsilateral, non-procedure-related stroke 
during up to 4 years of follow-up among patients who 
developed severe restenosis at any time during the 
first 2 years after treatment.7 However, in some patients, 
restenosis might only have been diagnosed after the 
stroke had occurred. Therefore, we chose an alternative 
approach by comparing the risk from the time of 
diagnosis of restenosis onwards with the risk in patients 
who did not develop restenosis.
When we analysed outcomes in each treatment group 
separately, the increase in stroke risk in patients with 
restenosis was raised significantly after endarterectomy, 
but not after stenting. However, the formal test for 
statistical interaction between the type of treatment and 
the increase in ipsilateral stroke risk caused by restenosis 
gave a p value of 0·10, indicating that the difference 
between endarterectomy and stenting was not significant 
(using the threshold p<0·05) and, therefore, could have 
arisen by chance. Nevertheless, the disparity in risk raises 
the question of whether pathological processes leading to 
restenosis might differ between operated and stented 
arteries. Restenosis occurring in the first 2 years after 
endarterectomy is attributed commonly to neointimal 
hyperplasia characterised by a proliferation of smooth 
muscle cells, which was thought to be associated with 
a low risk of thromboembolic events.21–24 Restenosis 
occurring later is most likely caused by recurrent 
atherosclerosis. In ICSS, however, most occurrences of 
restenosis in both treatment groups arose in the first 
2 years and, nonetheless, restenosis increased the risk of 
stroke in the surgery group. Proliferation of smooth 
muscle cells has also been noted in a patient with severe 
restenosis 15 months after balloon angioplasty of the 
internal carotid artery,25 suggesting similarities with post-
surgical restenosis, at least in the early phase. It is possible 
thougAh that the newly formed endothelium on the stent 
surface confers some protection against thrombo embolic 
events in the case of luminal narrowing. 
In a meta-analysis of summary data from several other 
randomised trials,26 the risk of stroke was increased 
after a diagnosis of severe (≥70%) restenosis after 
endarterectomy, but not after stenting. This observation 
of a differential risk corroborates our findings, although 
the effect of moderate or higher (≥50%) restenosis was 
not examined. Consistent with the findings of this 
meta-analysis, the risk of ipsilateral stroke in patients 
with restenosis after endarterectomy remained relatively 
low in ICSS, at just over 1% per year. Pooled time-to-event 
analyses of individual patient-level data from randomised 
trials could yield further insight into duplex criteria 
identifying patients with restenosis at higher risk of 
stroke and the difference in stroke risk associated with 
restenosis after stenting and endarterectomy.
Our study had some limitations. First, velocity 
measurements were analysed as recorded by local 
investigators, and we were not able to review duplex 
images to check that angle correction was done in all 
cases. However, our methodology accords with that used 
in several other studies.8,13,27 Second, the true effect of 
restenosis on risk for recurrent stroke could have been 
underestimated because restenosis might only have been 
diagnosed after a stroke occurred, because we used a 
time-updated covariate model. For the same reason, the 
effect of severe restenosis (vs moderate or higher 
restenosis) on subsequent stroke could have been 
underestimated because restenosis might only have been 
moderate at the time of the last ultrasound scan and 
could have become severe before the event occurred. 
Third, our study could have been underpowered to detect 
a possible difference in severe restenosis between 
stenting and endarterectomy and an effect of severe 
restenosis on stroke risk. Fourth, despite the noted 
increase in stroke risk in patients with restenosis, our 
data neither allow us to draw firm conclusions on the 
usefulness of regular ultrasound follow-up after carotid 
revascularisation nor justify repeat revascularisation in 
patients with restenosis. A larger sample size is needed 
to establish treatment-specific ultrasound velocity cutoffs 
identifying patients at risk for recurrent stroke, which 
will require a combined analysis of patient-level data 
from several randomised trials.
In conclusion, moderate or higher (≥50%) restenosis 
occurred more frequently after stenting than after 
endarterectomy. Restenosis after revascularisation of 
the carotid artery increased significantly the risk for 
subsequent stroke. However, it remains unclear from 
our results whether this risk is common to both 
procedures or whether it is significantly more 
pronounced in patients who undergo endarterectomy.
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